Condition
Obesity
Elevated High-sensitivity C-reactive Protein (hsCRP)
Locations
Netherlands
Start date
06/07/2026
Identifiers
Trial ID NN6022-8271,
NCT number NCT07693868,
Eudract number Not Available
NCT number NCT07693868,
Eudract number Not Available
Summary
This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.
Trial Overview:
Treatment
DRUG: NNC6022-0004
DRUG: Placebo
Study type
INTERVENTIONAL
Trial duration
Jul 06 2026 - Aug 03 2027
Participants
128
Phase
I
Are you eligible?
Gender
Male and female
Age
18 to 65 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.